Key Industry Experts Share Their Insights on How Inhalation Drug Delivery Systems Are Gathering Momentum

LONDON, July 29, 2013 /PRNewswire/ --

With the global market for asthma and COPD drugs set to reach $47bn in 2017, inhalation drug delivery systems are gathering momentum as pharmaceutical companies develop faster acting and more effective orally inhaled products. It is crucial for market players to keep abreast of the latest advances in inhaled therapy, in order to successfully grow the business and stay ahead of the competition.

According to Donovan Yates, Chief Executive Officer of KAER Biotherapeutics and one of the distinguished speakers at the upcoming CPhI Inhalation Drug Delivery Conference, "The search for proven healthcare solutions that change patient outcomes while reducing treatment costs is eternal.  The pharmaceutical industry is struggling in advancing its own solutions because of the complex and expensive drug development process.  The trending in pharmacoeconomics and patent cliffs have also added to the significant cost pressures for Pharma, as the industry is constantly looking for new technologies to resolve these issues."

CPhI Worldwide's Inhalation Drug Delivery Conference is an excellent opportunity to explore various solutions, as well as gain important insights into every essential aspect of pulmonary drug delivery. From formulation of MDIs and DPIs, particle engineering and establishing bioavailability and bioequivalence, to regulatory compliance, innovative filling techniques and device development - this inaugural CPhI two-day conference will provide delegates from all over the world with a step-by step guide on how to achieve commercial success.

"It will be useful in concentrating pharmaceutical scientists' minds on the issues involved and providing them with an understanding of how to progress an idea.  It also allows scientists and academia from various parts of the world to come together and discuss in-depth this specific area of research," says Brian Jones, Scientific Adviser for Qualicaps Europe.

David Harris, Head of Respiratory Drug Delivery of Team Consulting refers to the upcoming conference as "a good way to raise awareness of companies' offerings, meet new and existing clients, share knowledge and find out about the latest research."

Whether your business is focused on pharmaceutical, clinical and formulation science or you operate in inhalation device development, the conference programme is uniquely tailored to the industry's current, specific needs, providing practical knowledge, new learning opportunities and unprecedented topical content.

For full programme including a list of the expert speakers and to register please visit http://www.cphi-drugdelivery.com

About CPhI Conferences:

CPhI Conferences deliver the latest pharma market insight, in-depth case studies and exceptional networking opportunities through a programme of high-level conferences. The worldwide series of events, spanning four continents, provides the optimum forum for you to learn, make new business connections and identify the latest growth opportunities. Delivered by expert teams in each region, every conference is extensively researched with leading professionals, ensuring that CPhI Conferences tackle the most business critical issues facing the pharma industry today.

http://www.cphiconferences.com/

SOURCE CPhI Conferences